Advertisement

Topics

Biogen shares fall after unexpected 'variability' in Alzheimer's studies

05:22 EST 15 Feb 2018 | BioPharmaDive

Company executives insisted the pre-planned check did not change their confidence in aducanumab, which has become Biogen's key pipeline asset.

Original Article: Biogen shares fall after unexpected 'variability' in Alzheimer's studies

NEXT ARTICLE

More From BioPortfolio on "Biogen shares fall after unexpected 'variability' in Alzheimer's studies"

Advertisement
Quick Search
Advertisement
Advertisement